The methods currently used to diagnose and characterize lung cancer have limitations and may be inaccurate^1-4. Low concordance exists among laboratories and lack of concurrence is found among pathologists¹. In one study, up to 40% of squamous or adenocarcinoma of the lung were reclassified when evaluated by a second pathologist¹. The use of biological markers in addition to morphological analysis is also problematic since none of these markers has a satisfactory degree of sensitivity and specificity^5,6. In many cases only samnples collected by cytological or biopsy procidures are available. Sample quantity limitations present within these specimens make the differential diagnosis even more difficult⁴.

Unlike the methods currently used, miRview® lung provides a differential diagnosis with:

• Fast, standardized, and objective classification
• The highest level of accuracy
• Simple interpretation
• Routine sample preparation

The miRview® lung assay uses quantitative real-time PCR (qRT-PCR) to determine the expression of microRNAs in tumor tissue. The sensitivity and specificity of this assay have been shown to be 93.7% and 98%, respectively.

miRview® lung is based on formalin-fixed paraffin-embedded (FFPE) tumor samples from pathological and cytological procedures, the current standard for preserving tumors in the pre- and post-op settings. FFPE samples require minimal preparation to be analyzed by our experts and can be easily shipped via any air courier.

1. Stang A, Pohlabeln H, Müller KM, Jahn I, Giersiepen K, Jöckel KH. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer. 2006;52(1):29-36.
2. Field RW, Smith BJ, Platz CE, et al. Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst. 2004;96(14):1105-1107.
3. Perelman M, Rosenwald S, Spector Y, et al. MicroRNA biomarkers for differential diagnosis of lung tumors. Presented at: United States and Canadian Academy of Pathology Annual Meeting; March 7-13, 2009; Boston, MA. Abstract 1630.
4. Stoll LM, Johnson MW, Burroughs F, Li QK. Cytologic diagnosis and differential diagnosis of lung carcinoid tumors a retrospective study of 63 Cases with histologic correlation. Cancer Cytopathol. 2010:118(6):457-67.
5. Tanca A, Addis MF, Pagnozzi D, Cossu-Rocca P, Tonelli R, Falchi G, Eccher A, Roggio T, Fanciulli G, Uzzau S. Proteomic analysis of formalin-fixed, paraffin-embedded lung neuroendocrine tumor samples from hospital archives.J Proteomics. 2011:74(3):359-70.
6. Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM. Bronchopulmonary neuroendocrine tumors.Cancer.2008:113(1):5-21.